Cytomegalovirus (CMV) drug resistance mutation maps are updated with recent information
for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor …

An increasing volume of information correlating CMV genotypes and drug susceptibility
phenotypes is becoming available. This will improve the interpretation of sequence-based …

Antiviral therapy for cytomegalovirus (CMV) plays an important role in the clinical
management of solid organ and hematopoietic stem cell transplant recipients. However …

Drug resistant strains of human cytomegalovirus (HCMV) in patients at risk may increasingly
develop into a problem in the clinical setting. Genotypic resistance testing is becoming the …

In immunosuppressed hosts, the development of multidrug resistance complicates the
treatment of cytomegalovirus (CMV) infection. Improved genotypic detection of impending …

The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …

Drug‐resistant cytomegalovirus (CMV) should be considered when viral shedding persists
after several weeks of therapy. The problem is most likely to arise in the setting of a severely …

Technical advancements can enhance the accurate and timely genotypic detection of drug
resistance. Antivirals undergoing clinical trial offer the prospect of new viral targets and drug …

Human cytomegalovirus (HCMV) is a significant pathogen in immunocompromised
individuals, with the potential to cause fatal pneumonitis and colitis, as well as increasing the …

Letermovir (LMV) is an experimental cytomegalovirus terminase inhibitor undergoing phase
3 clinical trials. Viral mutations have been described at UL56 codons 231 to 369 that confer …